

Ref: EPL/CS/SE/0044/2026

Date: May 08, 2026

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - ESG Rating

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Part A Para A of Schedule III and SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, we hereby inform you that NSE Sustainability Ratings & Analytics Limited, a SEBI registered Environmental, Social, and Governance (ESG) Rating Provider, has voluntarily and independently assigned ESG rating of 21 to the Company, for the Financial Year 2024-25, based on information available in public domain.

This disclosure is being made based on the information received by the Company vide email dated May 07, 2026, about such rating.

You are requested to take the above information on your records.

Thanking you,

For Emcure Pharmaceuticals Limited

Amruta Yangelwar
Company Secretary & Compliance Officer
ICSI Membership Number: A25687

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251